By Reuters
Copyright reuters
CompaniesBristol-Myers Squibb CoSandoz Group AGUcb SA
SHANGHAI, Sept 17 (Reuters) – U.S. drugmaker Bristol Myers Squibb (BMY.N), opens new tab said on Tuesday it has signed an agreement to sell its 60% ownership stake in a pharmaceutical joint venture in China.
“As part of our long-term strategy, we continue to align our resources to support evolving business needs across our global network,” a spokesperson for the company said in an emailed response to Reuters’ queries about a local media report.
Advertisement · Scroll to continue
The spokesperson said Bristol Myers was “committed to supporting all impacted employees” and was “grateful for their contributions”, but said it does not comment on transaction details, citing policy.
Established in 1982, the Sino-American Shanghai Squibb Pharmaceuticals Limited (SASS) joint venture was the first Sino-U.S. pharmaceutical joint venture, opens new tab in the country.
A manufacturing facility in Shanghai, part of the venture, was one of China’s first modern pharmaceutical manufacturing bases and was key to bringing new technology expertise to China, Bristol Myers said in its 2010 annual report., opens new tab
The venture has supplied a variety of medicines including metformin, opens new taband paracetamol, opens new tab, research papers reviewed by Reuters showed.
Advertisement · Scroll to continue
Get the key points from this story with Reuters AI
Bristol Myers would be the latest drugmaker planning to sell off some Chinese assets following supply chain disruptions, China’s economic slowdown and price cuts to get state insurance listing.
Its agreement follows similar actions by foreign firms including the Swiss Group Sandoz (SDZ.S), opens new tab and Belgium’s UCB (UCB.BR), opens new tab.
Ad Break Coming Up
NEXT StayNext
OffEnglish
180p288p360p480p540p576p720pHD1080pHDAuto (180p)
About ConnatixV2044314819
About ConnatixV2044314819
Continue watchingafter the adVisit Advertiser websiteGO TO PAGE
Reporting by Andrew Silver in Shanghai; Editing by Jacqueline Wong
Purchase Licensing Rights